Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate safety and tolerance of M2ES with TC regimen in advanced NSCLC.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Criteria

Inclusion Criteria:

1. Aged 18-70 years old;

2. Patients with Ⅲ/Ⅳ NSCLC confirmed by histopathology or cytology who ware naive or previous chemotherapy without TC regimen;

3. No contraindication for chemotherapy;

4. ECOG performance scale 0-2;

5. No history of anti-angiogenesis therapy;

6. Patients are voluntary to participate and sigh the informed contents.

Exclusion Criteria:

1. Concurrent use of other anti-cancer agents;

2. Allergic history to M2ES and biological agents;

3. Pregnant or breast-feeding women;

4. With other malignancy;

5. With severe cardiopulmonary disease;

6. Uncontrolled brain metastasis patients;

7. Other conditions that are regarded for exclusion by the trialists.